Kronos Bio
-
Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year
The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
-
Kite Pharma founder’s venture capital firm closes new $600M fund
The new fund, announced Thursday by Arie Belldegrun’s Vida Ventures, brings the total amount of money raised to approximately $1 billion.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Kronos Bio bags $105M in Series A round for platform technology
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after “undruggable” targets.
-
Which New York City healthcare companies raised the most dough from investors in Q2?
A New York City Health Business Leaders report details the top 12 healthcare financings of the second quarter, including investments in organizations like RubiconMD, Kronos Bio and Thrive Global.
-
Gilead veteran looks to move ahead in new role as startup CEO
Assuming all goes well, potential prostate cancer drug candidate could enter clinic by end of next year, Norbert Bischofberger says.